# Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

> **NCT04573231** · PHASE2 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 13 (estimated)

## Conditions studied

- Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** 18F-DCFPyL

## Key facts

- **NCT ID:** NCT04573231
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-24
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04573231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04573231, "Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04573231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*